Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL4884014 | 1.00 | MGLL (0.42) | MGLLCA12CA1CA9CA2 | |
| SCHEMBL1871136 | 1.00 | — | — | |
| Fluoride SCHEMBL7482976 | 1.00 | — | — | |
| SCHEMBL1870030 | 0.73 | — | — | |
| SCHEMBL3364313 | 0.67 | — | — | |
| SCHEMBL10599432 | 0.67 | MGLL (0.47) | MGLLCA12CA1CA9CA2 | |
| Fluoride SCHEMBL3216899 | 0.67 | — | — | |
| SCHEMBL236146 | 0.67 | MGLL (0.47) | MGLLCA12CA1CA9CA2 | |
| SCHEMBL11829900 | 0.67 | MGLL (0.40) | MGLLCA12CA1CA9CA2 | |
| Hydrogen Peroxide SCHEMBL11793831 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160695-B2 | Synthesis of meta-substituted [18F]-3-fluoro-4-aminopyridines by direct radiofluorination of pyridine N-oxides | THE UNIVERSITY OF CHICAGO (US) | 2018-12-25 | — | — | US | claimed |
| US-20170355648-A1 | SYNTHESIS OF META-SUBSTITUTED [18F]-3-FLUORO-4-AMINOPYRIDINES BY DIRECT RADIOFLUORINATION OF PYRIDINE N-OXIDES | THE UNIVERSITY OF CHICAGO | 2017-12-14 | — | — | US | claimed |
| CN-100543032-C | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2009-09-23 | — | — | CN | claimed |
| US-20080167488-A1 | Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | claimed |
| EP-1912930-A1 | PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES. | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007013848-A1 | PROCESS FOR THE PREPARATION OF GEMINAL ((DIFLUOROCYCLOALKYL)METHYL) AMINES. | ASTRAZENECA AB (SE) | 2007-02-01 | — | — | WO | claimed |
| CN-1358194-A | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2002-07-10 | — | — | CN | claimed |
| CN-1137797-A | Rapamycin derivatives useful as immunosuppressants | SANDOZ LTD (CH) | 1996-12-11 | — | — | CN | claimed |
| WO-2025111251-A1 | COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 | EXELIXIS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-119173253-A | Combination of allosteric and orthosteric EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-118317956-A | Bis (hetero) aryl thioether oxadiazines as fungicidal compounds | 拜耳公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116490507-A | Heterocyclic condensation CDC7 kinase inhibitors for the treatment of cancer | 薛定谔公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-0933364-A1 | Imidazolate sulfur difluorides | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0908448-A1 | Thermally stable aminosulfur trifluorides | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0905109-A1 | Fluorination with aminosulfur trifluorides | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1999-03-31 | — | — | EP | disclosed |
| CN-1191541-A | Synthesis modification of spinosyn compounds | DOWELANCO (US) | 1998-08-26 | — | — | CN | disclosed |
| CN-1187486-A | Difluoroprostaglundin Derivatives and their use | ASAHI GLASS CO LTD (JP) | 1998-07-15 | — | — | CN | disclosed |
| CN-1137797-A | Rapamycin derivatives useful as immunosuppressants | SANDOZ LTD (CH) | 1996-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167488-A1 | Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines | GMNN, GNMT, DNMT1 | MGLL 560/4885CA12 3328/4885CA1 3735/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | MGLL 3380/4885CA12 3915/4885CA1 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.